Inhibition of ATGL alleviates MASH via impaired PPARα signalling that favours hydrophilic bile acid composition in mice
Emmanuel D. Dixon(Medical University of Vienna), Michael Trauner(Medical University of Graz), Georg Busslinger(Austrian Academy of Sciences), Alexander D Nardo(Medical University of Vienna), G Grabner(University of Graz), Henkjan J. Verkade(Cystic Fibrosis Foundation), Guenter Haemmerle(University of Graz), Dagmar Kratky(Medical University of Graz), Thierry Claudel(Medical University of Vienna), Robert Zimmermann(BioTechMed-Graz), Veronika Mlitz(Medical University of Vienna), Alessandra Riva(University of Vienna), Helga Hinteregger(Medical University of Graz), Tatjana Stojaković, Claudia Fuchs(Medical University of Vienna), Joana Séneca(University of Vienna)
Cited by 33
Related Papers
Cardioprotection and lifespan extension by the natural polyamine spermidine
|Nature Medicine|2016|1.1k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
|Gastroenterology|2014|563
Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease
|Annual Review of Pathology Mechanisms of Disease|2018|561
Pathophysiological mechanisms of liver injury in COVID‐19
|Liver International|2020|399